[{"id":"be216cac-b6dd-4109-a60b-83756637bfdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03122717","created_at":"2021-01-17T17:16:14.303Z","updated_at":"2025-02-25T14:58:00.620Z","phase":"Phase 1/2","brief_title":"Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer","source_id_and_acronym":"NCT03122717","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • gefitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/09/2017","start_date":" 05/09/2017","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-09-26"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"53d80059-10cf-4b1e-809f-d51433276602","acronym":"RELAY","url":"https://clinicaltrials.gov/study/NCT02411448","created_at":"2021-01-17T17:40:04.195Z","updated_at":"2024-07-02T16:35:14.291Z","phase":"Phase 3","brief_title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","source_id_and_acronym":"NCT02411448 - RELAY","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 545","initiation":"Initiation: 05/06/2015","start_date":" 05/06/2015","primary_txt":" Primary completion: 01/23/2019","primary_completion_date":" 01/23/2019","study_txt":" Completion: 12/16/2024","study_completion_date":" 12/16/2024","last_update_posted":"2024-03-18"},{"id":"7218e546-77ae-4326-92dc-2bfe9ec5ace3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03647592","created_at":"2021-01-18T17:54:17.426Z","updated_at":"2024-07-02T16:35:25.192Z","phase":"","brief_title":"Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03647592","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • erlotinib • gefitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-27"},{"id":"7d41bb5c-8775-4bbb-9bda-315d6ca7d0d0","acronym":"SELECT-2","url":"https://clinicaltrials.gov/study/NCT04401059","created_at":"2023-12-27T18:16:50.631Z","updated_at":"2024-07-02T16:35:25.073Z","phase":"Phase 4","brief_title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","source_id_and_acronym":"NCT04401059 - SELECT-2","lead_sponsor":"Tian Xie","biomarkers":" EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR positive","tags":["EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 744","initiation":"Initiation: 11/09/2020","start_date":" 11/09/2020","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2023-12-27"},{"id":"5aa577f3-9cb1-4446-a2b3-1ebba57b798a","acronym":"SIIS","url":"https://clinicaltrials.gov/study/NCT01485809","created_at":"2021-01-18T06:12:38.051Z","updated_at":"2024-07-02T16:35:28.208Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy","source_id_and_acronym":"NCT01485809 - SIIS","lead_sponsor":"Seoul Veterans Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 10/01/2011","primary_completion_date":" 10/01/2011","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2023-11-24"},{"id":"f35e6550-13c5-46f1-8099-379452a3a89e","acronym":"ARCHER 1050","url":"https://clinicaltrials.gov/study/NCT01774721","created_at":"2021-01-17T17:11:15.852Z","updated_at":"2024-07-02T16:35:29.318Z","phase":"Phase 3","brief_title":"ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.","source_id_and_acronym":"NCT01774721 - ARCHER 1050","lead_sponsor":"Pfizer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 452","initiation":"Initiation: 05/09/2013","start_date":" 05/09/2013","primary_txt":" Primary completion: 07/29/2016","primary_completion_date":" 07/29/2016","study_txt":" Completion: 01/27/2022","study_completion_date":" 01/27/2022","last_update_posted":"2023-11-14"},{"id":"2bafa7f6-34b1-49c6-949e-a3fe4e4c7ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06071013","created_at":"2023-10-06T14:11:38.244Z","updated_at":"2024-07-02T16:35:34.351Z","phase":"Phase 2","brief_title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","source_id_and_acronym":"NCT06071013","lead_sponsor":"China Medical University Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Gilotrif (afatinib) • gefitinib • nintedanib"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 08/27/2026","primary_completion_date":" 08/27/2026","study_txt":" Completion: 08/27/2026","study_completion_date":" 08/27/2026","last_update_posted":"2023-10-06"},{"id":"649bdd51-d932-4cd8-882a-dae84b289293","acronym":"","url":"https://clinicaltrials.gov/study/NCT01833572","created_at":"2021-01-18T08:09:40.839Z","updated_at":"2024-07-02T16:35:43.371Z","phase":"Phase 2","brief_title":"Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)","source_id_and_acronym":"NCT01833572","lead_sponsor":"Fudan University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2023-07-12"},{"id":"71c0d56d-ad3c-4952-8f33-c4745404330b","acronym":"UpSwinG","url":"https://clinicaltrials.gov/study/NCT04179890","created_at":"2023-05-25T18:54:32.923Z","updated_at":"2024-07-02T16:35:47.178Z","phase":"","brief_title":"The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib","source_id_and_acronym":"NCT04179890 - UpSwinG","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 462","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 07/22/2021","study_completion_date":" 07/22/2021","last_update_posted":"2023-05-25"},{"id":"952c0c39-ad39-476d-90fc-c92d7fa765f6","acronym":"INSIGHT","url":"https://clinicaltrials.gov/study/NCT01982955","created_at":"2021-01-17T17:35:00.093Z","updated_at":"2025-02-25T14:49:47.416Z","phase":"Phase 1/2","brief_title":"Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)","source_id_and_acronym":"NCT01982955 - INSIGHT","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • MET amplification • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gefitinib • pemetrexed • Tepmetko (tepotinib)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 12/23/2013","start_date":" 12/23/2013","primary_txt":" Primary completion: 12/12/2017","primary_completion_date":" 12/12/2017","study_txt":" Completion: 10/14/2021","study_completion_date":" 10/14/2021","last_update_posted":"2022-11-08"},{"id":"48b8d938-7f8b-4bf9-a8a6-3d05476c8d31","acronym":"","url":"https://clinicaltrials.gov/study/NCT03758287","created_at":"2021-01-17T17:24:54.380Z","updated_at":"2024-07-02T16:36:08.487Z","phase":"Phase 1/2","brief_title":"Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative","source_id_and_acronym":"NCT03758287","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR T790M negative","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • ningetinib (CT053PTSA)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2022-06-22"},{"id":"d5fb608c-cb96-4e4a-a0ee-288654bacebe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02447419","created_at":"2021-01-18T11:43:46.510Z","updated_at":"2024-07-02T16:36:08.665Z","phase":"Phase 2","brief_title":"Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors","source_id_and_acronym":"NCT02447419","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 12/03/2014","start_date":" 12/03/2014","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2022-06-15"},{"id":"d6bf4390-80d2-48a6-a20b-b3b33e8ad438","acronym":"","url":"https://clinicaltrials.gov/study/NCT00522145","created_at":"2021-01-18T01:53:09.959Z","updated_at":"2024-07-02T16:36:10.496Z","phase":"Phase 2","brief_title":"Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib","source_id_and_acronym":"NCT00522145","lead_sponsor":"Kadmon Corporation, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • tesevatinib (KD019)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 05/01/2007","start_date":" 05/01/2007","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2022-05-13"},{"id":"d1e976df-da04-4b75-a33f-43e3952514c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02804776","created_at":"2021-01-18T13:45:12.067Z","updated_at":"2024-07-02T16:36:29.580Z","phase":"Phase 2","brief_title":"PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery","source_id_and_acronym":"NCT02804776","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 01/27/2015","start_date":" 01/27/2015","primary_txt":" Primary completion: 02/21/2018","primary_completion_date":" 02/21/2018","study_txt":" Completion: 02/21/2018","study_completion_date":" 02/21/2018","last_update_posted":"2021-06-02"},{"id":"0a1e7551-4f28-4fcb-afa2-2527d2492114","acronym":"","url":"https://clinicaltrials.gov/study/NCT04874844","created_at":"2021-05-06T12:52:59.177Z","updated_at":"2024-07-02T16:36:30.558Z","phase":"Phase 2/3","brief_title":"JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety","source_id_and_acronym":"NCT04874844","lead_sponsor":"Beijing Dongfang Biotech Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • JY025"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 03/30/2022","primary_completion_date":" 03/30/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2021-05-10"},{"id":"98b338ca-7e46-4a04-b381-f7878ee43d62","acronym":"CINC280X2202","url":"https://clinicaltrials.gov/study/NCT01610336","created_at":"2021-01-18T06:53:42.388Z","updated_at":"2024-07-02T16:36:32.157Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment","source_id_and_acronym":"NCT01610336 - CINC280X2202","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • Tabrecta (capmatinib)"],"overall_status":"Completed","enrollment":" Enrollment 161","initiation":"Initiation: 04/05/2012","start_date":" 04/05/2012","primary_txt":" Primary completion: 06/10/2016","primary_completion_date":" 06/10/2016","study_txt":" Completion: 05/27/2020","study_completion_date":" 05/27/2020","last_update_posted":"2021-04-08"},{"id":"3fe819ea-51da-4422-9467-960a5f22ce0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02747953","created_at":"2021-01-18T13:27:46.249Z","updated_at":"2024-07-02T16:36:33.065Z","phase":"Phase 2","brief_title":"Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib","source_id_and_acronym":"NCT02747953","lead_sponsor":"Samsung Medical Center","biomarkers":" EGF","pipe":"","alterations":" ","tags":["EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Gilotrif (afatinib) • gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2021-03-19"},{"id":"435cac05-e299-4e5a-bcbc-5142d45d7a95","acronym":"LADIE","url":"https://clinicaltrials.gov/study/NCT01556191","created_at":"2021-01-18T06:35:19.191Z","updated_at":"2024-07-02T16:36:36.406Z","phase":"Phase 2","brief_title":"Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR","source_id_and_acronym":"NCT01556191 - LADIE","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 379","initiation":"Initiation: 05/15/2012","start_date":" 05/15/2012","primary_txt":" Primary completion: 05/15/2018","primary_completion_date":" 05/15/2018","study_txt":" Completion: 06/17/2020","study_completion_date":" 06/17/2020","last_update_posted":"2021-01-08"},{"id":"6949e70b-8abb-4368-b241-09f145cf8fe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00052208","created_at":"2021-01-18T00:05:43.538Z","updated_at":"2024-07-02T16:36:39.349Z","phase":"Phase 1/2","brief_title":"Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme","source_id_and_acronym":"NCT00052208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 158","initiation":"Initiation: 03/01/2002","start_date":" 03/01/2002","primary_txt":" Primary completion: 06/01/2005","primary_completion_date":" 06/01/2005","study_txt":"","study_completion_date":"","last_update_posted":"2020-10-30"},{"id":"63192aae-11a2-4f2a-8e75-d623a9a7e540","acronym":"","url":"https://clinicaltrials.gov/study/NCT00553254","created_at":"2021-01-18T02:00:56.086Z","updated_at":"2024-07-02T16:36:39.987Z","phase":"Phase 2","brief_title":"Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer","source_id_and_acronym":"NCT00553254","lead_sponsor":"Pfizer","biomarkers":" HER-2 • KRAS","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • KRAS wild-type","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • Vizimpro (dacomitinib)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 02/05/2008","start_date":" 02/05/2008","primary_txt":" Primary completion: 08/03/2010","primary_completion_date":" 08/03/2010","study_txt":" Completion: 07/17/2014","study_completion_date":" 07/17/2014","last_update_posted":"2020-10-19"},{"id":"c3d6d08b-bfce-44f5-99da-bdf9ee4a7e5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01544179","created_at":"2021-01-18T06:31:46.905Z","updated_at":"2024-07-02T16:36:40.674Z","phase":"Phase 3","brief_title":"A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone","source_id_and_acronym":"NCT01544179","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gefitinib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 265","initiation":"Initiation: 03/15/2012","start_date":" 03/15/2012","primary_txt":" Primary completion: 05/05/2014","primary_completion_date":" 05/05/2014","study_txt":" Completion: 11/20/2019","study_completion_date":" 11/20/2019","last_update_posted":"2020-09-25"},{"id":"04bf9f33-c206-4fb2-ae58-5f4002359115","acronym":"","url":"https://clinicaltrials.gov/study/NCT03267654","created_at":"2021-01-18T16:08:27.490Z","updated_at":"2024-07-02T16:36:42.458Z","phase":"Phase 2","brief_title":"Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance","source_id_and_acronym":"NCT03267654","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" EGFR • BCL2","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • BCL2L11 deletion","tags":["EGFR • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • BCL2L11 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gefitinib • AiTan (rivoceranib)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 10/12/2017","start_date":" 10/12/2017","primary_txt":" Primary completion: 10/20/2020","primary_completion_date":" 10/20/2020","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2020-08-03"},{"id":"8eee1310-b3a6-461c-b8ac-419a61400346","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457337","created_at":"2021-01-18T17:02:43.295Z","updated_at":"2024-07-02T16:36:43.369Z","phase":"Phase 2","brief_title":"S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC","source_id_and_acronym":"NCT03457337","lead_sponsor":"Henan Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 03/28/2018","start_date":" 03/28/2018","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 10/31/2021","study_completion_date":" 10/31/2021","last_update_posted":"2020-07-10"}]